"Podophyllotoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
Descriptor ID |
D011034
|
MeSH Number(s) |
D02.455.426.559.389.140.450.777 D02.455.426.559.847.638.960.675 D04.615.638.960.675
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Podophyllotoxin".
Below are MeSH descriptors whose meaning is more specific than "Podophyllotoxin".
This graph shows the total number of publications written about "Podophyllotoxin" by people in this website by year, and whether "Podophyllotoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Podophyllotoxin" by people in Profiles.
-
Podophyllotoxin: History, Recent Advances and Future Prospects. Biomolecules. 2021 04 19; 11(4).
-
Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy. Nat Prod Rep. 2021 03 01; 38(3):470-488.
-
Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Med Res Methodol. 2018 11 06; 18(1):125.
-
Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. EuroIntervention. 2018 Aug 03; 14(5):e538-e545.